{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-136957","form_type":"8-K","ticker":"HYPD","cik":"0001682639","company_name":"HYPERION DEFI, INC.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.666266+00:00","generated_at":"2026-06-28T10:01:52.176830+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eyenovia reports Q3 net loss $5.6M; Chairman Eshelman to step down","bullets":["Net loss of $5.6M ($0.21 per share) vs $5.1M ($0.23) in Q3 2020; R&D $3.5M, G&A $2.4M.","Cash $21.4M at Sept 30; expects to fund MydCombi resubmission, MicroLine Phase 3, and manufacturing.","First patient enrolled in VISION-2 Phase 3 presbyopia trial; topline data expected mid-2022.","FDA issued Complete Response Letter reclassifying MydCombi as drug-device combo; expedited resubmission planned early 2022.","Chairman Fred Eshelman to resign by end of 2021; not due to disagreement; Board search to follow."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-136957","json":"https://secwatch.observer/filing/0001104659-21-136957.json","markdown":"https://secwatch.observer/filing/0001104659-21-136957.md","text":"https://secwatch.observer/filing/0001104659-21-136957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682639/000110465921136957/0001104659-21-136957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682639/000110465921136957/tm2132498d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:01:52.176830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0358b6aa73","claim":"Fred Eshelman resigned as Chairman of the Eyenovia Board at HYPERION DEFI, INC..","evidence_excerpt":"Dr. Fred Eshelman, who has served as Chairman of the Eyenovia Board since 2014, will step down from the Board by the end of 2021 to pursue other professional interests.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682639/000110465921136957/0001104659-21-136957-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Eyenovia Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}